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To evaluate the efficacy and common side effects of intermittent clonazepam 
in febrile seizures.
Materials & Methods
This study was an experimental trial designed to determine the efficacy of 
intermittent clonazepam in febrile seizures .Thirty patients with an age range 
of 6 months to 5 years (60% male, 40% female) were studied. Children with a 
history of psychomotor delay, abnormal neurological examination, a history of 
antiepileptic drug consumption, and afebrile seizures were excluded from the 
study. Patients received a single dose of prophylactic Clonazepam (0.05 mg/kg/
day) on the first day of febrile illness and twice daily during the course of fever. 
An antipyretic medication (Acetaminophen) was advised if fever exceeded 
38oC. Patients were followed up for one year after the study inclusion date.
Results
Three patients were excluded from study since they didnot follow the tritment 
and three patients experienced afebrile seizures. Twenty four patients had 162 
febrile episodes during the course of the study and all patients were seizure-free 
after 1 year. 
Conclusion
Clonazepam was 100% effective but lethargy and ataxia were common side 
effects in patients. Fortunately, their parents continued treatment because they 
had prior awareness of the possible side effects of clonazepam. Clonazepam is 
efficacious as an intermittent therapy for febrile seizures if parents are informed 
of its side effects. 
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A febrile seizure (FS) is defined as seizure activity associated with a fever in a 
previously healthy child between 6 months and 5 years of age, who has no evidence 
of intracranial infection or defined cause, and no prior history of afebrile seizures. 
Another definition from the International League Against Epilepsy (ILAE) is a 
seizure occurring in childhood after 1 month of age associated with a febrile illness 
not caused by an infection of the central nervous system (CNS), without a previous 
neonatal seizure or a previous unprovoked seizure, and not meeting the criteria 
for other acute symptomatic seizures (1). Febrile seizures are the most common 
convulsion event in childhood; they occur in 2-5% of the children below 5 years of 
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age. The probability of recurrent simple febrile seizures 
is 50% for children younger than 12 months at the time 
of the first seizure and 30% for children older than 12 
months. Of those children who do have a second febrile 
seizure, 50% have a chance of having at least 1 additional 
recurrence (2). Risk factors for recurrent febrile seizures 
include (1) those with the first seizure occurring below 
the age of 12 months, (2) family history of febrile seizures 
in a first-degree relative, and (3) children experiencing 
seizures with a low grade fever, a brief duration between 
the fever onset and the initial seizure, and multiple initial 
febrile seizures during the same episode (1, 2, 3).
Although the etiology of febrile seizures is unknown, 
it is thought to be genetic with an autosomal dominant 
pattern of inheritance with reduced penetrance. Although 
the exact molecular mechanisms of febrile seizures are 
yet to be understood, underlying mutations have been 
found in genes encoding sodium channels and gamma-
aminobutyric acid A receptors. Both of these channels 
are also associated with severe myoclonic epilepsy 
of infancy, which often begins with prolonged febrile 
seizures (either complex febrile seizures or febrile status) 
and with subsequent seizures precipitated by fever (3, 
4).
Febrile seizures are very strongly related to mesial 
temporal sclerosis. There are reports of a relationship 
between temporal lobe epilepsy and mesial temporal 
sclerosis and prolonged febrile seizure in infancy. Some 
studies have shown a relationship between complex 
infantile febrile seizures and mesial temporal sclerosis. 
Patients with complex febrile seizures (duration >15 
min, evidence of focal or lateralized convulsive activity, 
or >3 seizures within 24 h) have an increased incidence 
of mesial temporal sclerosis. Based on the number of 
complex features, the incidence of mesial temporal 
sclerosis in patients who have had complex febrile 
seizures is 4-50 %. (5, 6, 7, 8).
The goal of long-term treatment is to prevent recurrent 
febrile seizures. This is achieved either by continuous 
long-term anticonvulsant therapy or intermittent 
prophylaxis. Continuous anticonvulsant treatment may 
be effective for reducing recurrence in children with a 
history of simple febrile seizures, but is associated with 
adverse effects. For example, Phenobarbital is associated 
with cognitive impairments and behavioral adverse 
effects (e.g., hyperactivity, irritability, aggressiveness). 
Doses of primidone at 15-20 mg/kg reduce the 
recurrence of febrile seizures. Side effects of Primidone 
include behavioral disturbances, irritability and sleep 
disturbances. Sodium valproate is effective in the 
prevention of recurrent febrile seizures. Adverse effects 
of sodium valproate are fatal hepatotoxicity, pancreatitis 
and gastrointestinal disturbances. Therefore, continuous 
therapy is effective in the prevention of simple febrile 
seizures in children but is not recommended because 
the risk for anticonvulsant toxicity outweighs its 
possible benefits (1-3).   Benzodiazepines administered 
intermittently, only during the febrile episodes, have 
been found effective in preventing the recurrence of 
febrile seizures. Diazepam has been commonly used 
either orally or rectally, but high doses of Diazepam 
are required (1 mg/kg/day divided into 3 doses) for 
prophylaxis. Since children are confused and ataxic after 
taking the first dose of Diazepam, their parents usually 
discontinue it. Many studies have reported the efficacy 
and safety of intermittent Clobazam in febrile seizures 
(9, 10).
Clonazepam is a benzodiazepine with a long half-life. 
Duration of action after a single dose is determined by 
redistribution rather than metabolism. Clonazepam is 
rapidly and completely absorbed after oral administration. 
Maximum plasma concentrations of clonazepam are 
reached within 1 to 4 hours after oral administration (11, 
12). We studied the effect of oral Clonazepam for the 
prophylaxis of febrile seizures, because the half-life of 
Clonazepam is prolonged and even a single dose/day is 
enough for the prevention of seizures during a febrile 
illness. 
 
Materials & Methods  
In an experimental study between October 2005 and 
March 2006, thirty patients were enrolled from the 
outpatient child neurology clinic and inpatient emergency 
department in a teaching hospital (Alzahra Hospital), 
after obtaining clearance from the ethical committee of 
the institution. Inclusion criteria were children between 
6 months and 5 years with one or more episodes of FS. 
Children less than 1 year of age at the time of the first 
attack and also children who were older than 1 year with 
two or more episodes of FS (with 50% chance of relapse) 
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were selected. Patients with intracranial infection, mental 
retardation, developmental delay, past history of afebrile 
seizures, systemic diseases (renal or hepatic dysfunction), 
and those taking antiepileptic drugs were excluded from 
the study. All patients had normal neurological exams 
and a negative family history of afebrile seizures. 
Clonazepam (0.05 mg/kg/day) was administered orally 
in a single dose on the first day of the disease. The same 
amount of Clonazepam was divided in 2 doses for oral 
administration on the following days of disease until 
the fever subsided (maximum 48-72 hours). Antipyretic 
treatment was given if fever exceeded 38o C. All patients 
were followed up every 3 months for a period of 1 year 
and the parents provided us with the episodes of febrile 
illnesses, seizures per febrile episode or afebrile seizure, 
and side effects of Clonazepam. Parents were informed 
of the side effects of Clonazepam, especially ataxia, 
sedation, and excessive salivation in young children.
Results
Thirty patients were enrolled in the study (characteristics 
of the patients are presented in Table 1 and 24 subjects 
continued the follow-up for 1 year. Three patients 
experienced afebrile seizures and continuous antiepileptic 
treatment was administered. Additionally, in three 
patients, seizure occurred before fever and their parents 
were not aware of their children's disease. Family history 
of FS was present in 50% of the cases. About 65% of the 
patients had simple febrile seizures and 25% had focal or 
multiple seizures (complex FS). There were 162 febrile 
episodes occurring in 24 patients during the follow-up 
period of 1 year but none of them experienced seizures. 
Drowsiness and ataxia were common side effects but 
none of the parents discontinued treatment. 
Discussion
Febrile seizures are the most common etiology of 
seizure in children less than 5 years of age, especially 
in those less than 3 year of age. Treatment of febrile 
seizure is a controversial issue, since it is a benign 
disease and the adverse effects of antiepileptic drug 
administration, especially in infancy, might be even 
worse than recurrence of the seizure. On the other hand, 
recurrence of febrile seizures poses a stressful situation 
for the child’s parents, either because they may be 
prolonged or frequent or evolved into status epilepticus. 
Children with simple febrile seizures do not have an 
increased mortality risk. However, seizures that are 
complex and occur before 1 year of age, or are triggered 
by a temperature of 39o C are associated with a two-fold 
increased mortality rate during the first 2 years after 
seizure occurrence (1). Children with febrile seizures 
have a slightly higher incidence of epilepsy compared 
to the general population (2% vs. 1%). Risk factors for 
epilepsy later in life include complex febrile seizure, 
family history of epilepsy or neurological abnormality, 
and developmental delay. Patients with 2 factors have up 
to a 10% chance of developing afebrile seizures (1-3). 
The risk of developing epilepsy is increased in children 
with a history of complex febrile seizures. A strong 
association exists between febrile status epilepticus 
or febrile seizures characterized by focal symptoms 
and later development of temporal lobe epilepsy (4, 
5). Parental anxiety regarding seizure recurrence and 
also lack of available medical services are the biggest 
problem for physicians who attend children with febrile 
seizures. The goal of long-term treatment is to prevent 
recurrent seizures, which is achieved either by long-
term anticonvulsant therapy or intermittent prophylaxis. 
Continuous anticonvulsant prophylaxis for FS can 
effectively prevent recurrence in patients, but the side 
effects of continuous prophylaxis with Phenobarbital or 
Sodium Valproate may be worse than recurrence of the 
seizure. Diazepam has been commonly used either orally 
or rectally. Intermittent oral Diazepam is recommended 
for the prophylaxis of FS. The required high dose of 
Diazepam (1 mg/kg/day), and its short half-life, which 
requires it to be divided up and administered three times 
daily, as well as its adverse effects including somnolence, 
ataxia and irritability, often causes parents to discontinue 
Diazepam after the first dose and consequently seizure 
recurs.
Clobazam has been used successfully an intermittent 
anti-convulsive therapy for prevention of febrile seizures 
(9, 10).  
Clonazepam has a plasma half-life of 20-43 h, and 
thus has a longer duration of action than Diazepam, 
Lorazepam or Midazolam. The oral absorption of 
Clonazepam is 80% or more. Peak levels are generally 
reached within 1-4 h after administration (11).
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The studies concerning the effect of Clonazepam on 
prophylaxis in FS are limited and only few studies have 
mentioned Clonazepam as an intermittent prophylaxis 
for FS. In addition, there is no solid work available. We 
studied the effect of Clonazepam in the prophylaxis of 
FS with a single dose on the first day of febrile disease, 
followed by the same amount divided into two doses 
on the next days. The results showed that it was very 
effective in the prophylaxis of FS. We recommend oral 
Clonazepam administration upon observing the first 
symptom of the disease before fever is detected by 
parents or as soon as possible when the child is febrile. 
Other studies are recommended to further evaluate 
Clonazepam in the prophylaxis of FS. 
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